Anthony Masaquel

1.2k total citations
76 papers, 868 citations indexed

About

Anthony Masaquel is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anthony Masaquel has authored 76 papers receiving a total of 868 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 25 papers in Pathology and Forensic Medicine and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anthony Masaquel's work include Lymphoma Diagnosis and Treatment (24 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Respiratory viral infections research (16 papers). Anthony Masaquel is often cited by papers focused on Lymphoma Diagnosis and Treatment (24 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Respiratory viral infections research (16 papers). Anthony Masaquel collaborates with scholars based in United States, Switzerland and Canada. Anthony Masaquel's co-authors include Parthiv J. Mahadevia, Caroline Breese Hall, Patricia Kipnis, Gabriel J. Escobar, Leonard B. Weiner, Amy Barrett, Ann Colosia, Mark J. Polak, Arona I. Ragins and Nazia Rashid and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Anthony Masaquel

68 papers receiving 849 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anthony Masaquel United States 18 413 380 247 135 85 76 868
Rebeca Font Spain 17 313 0.8× 93 0.2× 258 1.0× 194 1.4× 133 1.6× 34 884
Abigail Doucette United States 16 95 0.2× 427 1.1× 322 1.3× 99 0.7× 31 0.4× 64 971
Nicole Engel-Nitz United States 13 208 0.5× 103 0.3× 147 0.6× 119 0.9× 42 0.5× 40 767
Shadi Kolahdoozan Iran 14 243 0.6× 276 0.7× 573 2.3× 366 2.7× 64 0.8× 37 1.0k
Fiona Pearce United Kingdom 17 79 0.2× 347 0.9× 82 0.3× 111 0.8× 81 1.0× 66 751
Constance Engelking United States 15 110 0.3× 419 1.1× 604 2.4× 133 1.0× 51 0.6× 26 1.0k
Anant Ramaswamy India 17 221 0.5× 514 1.4× 605 2.4× 426 3.2× 73 0.9× 190 1.2k
Tom van der Hulle Netherlands 19 217 0.5× 240 0.6× 99 0.4× 265 2.0× 16 0.2× 69 1.6k
Nazım Serdar Turhal Türkiye 15 128 0.3× 311 0.8× 369 1.5× 181 1.3× 62 0.7× 69 800
Rena K. Fox United States 15 699 1.7× 60 0.2× 77 0.3× 133 1.0× 51 0.6× 26 1.0k

Countries citing papers authored by Anthony Masaquel

Since Specialization
Citations

This map shows the geographic impact of Anthony Masaquel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Masaquel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Masaquel more than expected).

Fields of papers citing papers by Anthony Masaquel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony Masaquel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Masaquel. The network helps show where Anthony Masaquel may publish in the future.

Co-authorship network of co-authors of Anthony Masaquel

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony Masaquel. A scholar is included among the top collaborators of Anthony Masaquel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony Masaquel. Anthony Masaquel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mahmoudjafari, Zahra, et al.. (2025). Glofitamab results in cost savings versus epcoritamab in relapsed/refractory diffuse large B-cell lymphoma: a total cost of care analysis ‡. Leukemia & lymphoma. 66(8). 1457–1464. 1 indexed citations
2.
3.
Gatwood, Justin, et al.. (2024). Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma. Journal of Medical Economics. 27(1). 738–745. 1 indexed citations
4.
Jin, Yanling, et al.. (2024). Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort. Cancer Medicine. 13(16). e70032–e70032. 1 indexed citations
5.
Burke, John M., Anthony Masaquel, Rongrong Wang, et al.. (2023). Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Clinical Lymphoma Myeloma & Leukemia. 23(11). e393–e404. 1 indexed citations
6.
7.
8.
Halwani, Ahmad, Vikas Patil, Catherine Li, et al.. (2019). Survival Patterns in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: Treatment Trajectories and Responses after the First Relapse. Blood. 134(Supplement_1). 1622–1622. 6 indexed citations
9.
10.
Huntington, Scott F., Torsten Strunz, Anthony Masaquel, et al.. (2019). PCN122 COST-EFFECTIVENESS OF A 24-MONTH FIXED DURATION OF VENETOCLAX IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES. Value in Health. 22. S78–S79. 1 indexed citations
11.
Samp, Jennifer C., et al.. (2018). PCN84 - TOTAL COST OF CARE AND BUDGET IMPACT FOR PATIENTS WITH CLL TREATED WITH VENETOCLAX. Value in Health. 21. S28–S28. 1 indexed citations
12.
Guzauskas, Gregory F., Anthony Masaquel, Per-Olof Thuresson, et al.. (2017). Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US?. Blood. 130. 5603–5603. 1 indexed citations
13.
Gallagher, Christopher, Tripthi Kamath, Anthony Masaquel, et al.. (2016). Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer. Breast Cancer Research and Treatment. 157(1). 145–156. 16 indexed citations
14.
Garrison, Louis P., Joseph B. Babigumira, Anthony Masaquel, et al.. (2015). The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer. Value in Health. 18(4). 541–546. 14 indexed citations
15.
Stenehjem, David D., Minkyoung Yoo, Sudhir Unni, et al.. (2014). Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer. Breast Cancer Targets and Therapy. 6. 169–169. 17 indexed citations
16.
Krilov, Leonard R., Anthony Masaquel, Leonard B. Weiner, et al.. (2014). Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis. BMC Pediatrics. 14(1). 261–261. 25 indexed citations
17.
Guérin, Annie, Deepa Lalla, Geneviève Gauthier, et al.. (2014). Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis. SpringerPlus. 3(1). 236–236. 4 indexed citations
18.
DiFranza, Joseph R., Anthony Masaquel, Amy Barrett, Ann Colosia, & Parthiv J. Mahadevia. (2012). Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children. BMC Pediatrics. 12(1). 81–81. 57 indexed citations
19.
Colosia, Ann, Anthony Masaquel, Caroline Breese Hall, et al.. (2012). Residential crowding and severe respiratory syncytial virus disease among infants and young children: A systematic literature review. BMC Infectious Diseases. 12(1). 95–95. 53 indexed citations
20.
Forbes, Michael L., et al.. (2010). Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life. Journal of Medical Economics. 13(1). 136–141. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebeca Font Breakdown of academic impact, for papers by Abigail Doucette Breakdown of academic impact, for papers by Nicole Engel-Nitz Breakdown of academic impact, for papers by Shadi Kolahdoozan Breakdown of academic impact, for papers by Fiona Pearce Breakdown of academic impact, for papers by Constance Engelking Breakdown of academic impact, for papers by Anant Ramaswamy Breakdown of academic impact, for papers by Tom van der Hulle Breakdown of academic impact, for papers by Nazım Serdar Turhal Breakdown of academic impact, for papers by Rena K. Fox
Rankless by CCL
2026